Immunotherapeutics, including Checkpoint inhibitors (CIs), show great promise in treating diseases including cancer, however, only a small percentage of patients respond well to these therapeutics. Because Immunotherapeutics are expensive and are associated with severe adverse side effects, screening is necessary to determine if a patient is likely to respond favorably to them. Current approaches to stratify patients based on likelihood to respond to CI treatment are ineffective and expensive.
Immunosignaturing is a unique platform that aims to detect complex patterns of antibodies produced in acute or chronic disease. The platform consists of a peptide microarray with 10,000 to over 300,000 peptides per assay and generates a vast amount of data.
Stephen Albert Johnston at the Biodesign Institute of Arizona State University has utilized the immunosignature platform as a simple and inexpensive test for stratifying patients who will respond well to immunotherapy. Using just a drop of blood, this test could screen patients to determine if they could be candidates for immunotherapy treatment. This test could also classify a patient as having a good prognosis or a poor prognosis, based on their immunosignature. This platform provides a better correlate than current approaches for determining immunotherapy responsiveness.
Given the cost and potential side effects, this simple and inexpensive test could have a huge impact in patient selection efforts for therapies.
• Test for stratifying patients that respond to immunotherapy including checkpoint inhibitors
• Prognostic testing based on immunosignatures
Benefits and Advantages
• Simple and inexpensive
• Can be quantified in multiple ways
o Number of motifs
o The percent of signature represented
o Total immune reactivity
• Only a drop of blood is needed
• May provide a better correlate than current approaches for determining immunotherapy responsiveness
For more information about the inventor(s) and their research, please see
Dr. Johnston’s directory webpage